CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company’s lead program, Vicineum™ for the treatment of non-muscle invasive carcinoma in situ (CIS) of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guérin (BCG).1
“Our interactions with the FDA during the fourth quarter provided us further clarity on the steps required to resubmit a BLA for Vicineum and to bring a therapy to market that we believe has the potential to save and improve the lives of patients,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “We have bolstered our team’s expertise in order to carry out that mission, and we look forward to executing our strategic priorities leading into, and coming out of, our upcoming Type C Meeting in March.”
US Regulatory Update
-
On October 29, 2021, Sesen Bio participated in a productive Chemistry, Manufacturing and Controls (CMC) Type A Meeting with the FDA. Following the meeting, the Company believes it has a clear understanding of what additional information regarding CMC is required for potential resubmission of a BLA. Other key takeaways from the meeting include the FDA confirming that:
- Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials.
-
Sesen Bio can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the Complete Response Letter (CRL) regarding the BLA for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and that any of these future trials can proceed while addressing CMC issues raised in the CRL.
-
On December 8, 2021, Sesen Bio participated in a productive Clinical Type A Meeting with the FDA. Following the meeting, the Company announced that it plans to conduct an additional Phase 3 clinical trial for potential resubmission of a BLA. Other key takeaways from the meeting include:
- The trial design may include a randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators’ choice of intravesical chemotherapy.
- The trial may include both patients who have received adequate BCG and patients who have received less than adequate BCG.
The anticipated randomized trial design is aligned with guidance the Company has received from the European Medicines Agency, which may help to coordinate the regulatory paths forward for Vicineum in the US and the European Union. The Company was also encouraged by the FDA to submit the final results from the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC with a BLA resubmission.
- On January 7, 2022, the FDA granted Sesen Bio’s request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive carcinoma in situ (CIS) of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.
Other Business Updates
-
On January 6, 2022, Sesen Bio disclosed that it achieved a $20 million milestone payment pursuant to the Company’s exclusive license agreement (Roche License Agreement) with Roche for legacy Interleukin-6 (IL-6) antagonist antibody technology owned by Sesen Bio. Following this milestone payment, Sesen Bio has cumulatively received $50 million in upfront and milestone payments, with an additional $220 million in potential future milestone payments remaining under the Roche License Agreement.
- On February 25, 2022, the Board of Directors (Board) of Sesen Bio disclosed the completion of an independent internal review conducted by outside counsel with the assistance of subject matter experts (Review). The Review took place over the course of five months, involved full cooperation from the Company’s management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. As a result of the Review, the Board continues to fully support the Company’s current management team and believes no changes or amendments relating to the Company’s prior disclosures to the Securities and Exchange Commission (SEC) or FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the Company’s BLA for Vicineum are warranted. The Company intends to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.
Fourth Quarter and Full-Year 2021 Financial Results
- Cash Position: Cash, cash equivalents and restricted cash were $162.6 million as of December 31, 2021, compared to $55.4 million as of December 31, 2020. The increase of $107.2 million was due primarily to net proceeds from at-the-market (ATM) offerings.
- R&D Expenses: Research and development expenses for the fourth quarter of 2021 were $7.0 million compared to $5.6 million for the same period in 2020. For the year ended December 31, 2021, research and development expenses were $25.3 million compared to $29.2 million for the same period in 2020. The full year decrease of $3.9 million was due primarily to lower costs associated with technology transfer and manufacturing ($7.4 million). This was partially offset by increases in employee-related compensation driven by increased headcount and the retention program implemented after receipt of the CRL in August 2021 ($2.1 million), regulatory and clinical consulting fees ($1.0 million) and certain other R&D expenses, none of which were individually material ($0.5 million).
- G&A Expenses: General and administrative expenses for the fourth quarter of 2021 were $8.6 million compared to $3.4 million for the same period in 2020. For the year ended December 31, 2021, general and administrative expenses were $29.4 million compared to $14.3 million for the same period in 2020. The full year increase of $15.1 million was due primarily to increases in employee-related compensation ($5.0 million), legal costs ($4.8 million), and marketing and commercial expenses driven by preparation for the commercial launch prior to receipt of the CRL ($4.1 million). Additionally, accounting services ($0.4 million), insurance expenses ($0.4 million), information technology expenses ($0.3 million) and other G&A expenses, none of which were individually material ($0.1 million), contributed to the increase.
- Restructuring Charge: Restructuring expenses were $5.5 million for the year ended December 31, 2021 compared to no restructuring expenses for the year ended December 31, 2020. The increase was due to one-time costs associated with the Restructuring Plan implemented in response to the CRL for severance and other employee-related costs ($2.8 million) and the termination of certain contracts ($2.7 million).
-
Non-Cash Related Expenses:
- Intangibles impairment charge for the year ended December 31, 2021 was $31.7 million. In light of the CRL, the Company performed an interim impairment test for In-Process Research and Development (IPR&D) assets, which resulted in the decrease in fair value of Vicineum’s US rights.
- The change in fair value of contingent consideration was a decrease of $56.8 million for the year ended December 31, 2021 compared to a decrease of $11.2 million for the same period in 2020. This was primarily due to management’s assessment of a lower probability of regulatory success and a refinement of timelines given the CRL.
- Income Tax Benefit (Provision): Benefit from income tax was $8.3 million for the year ended December 31, 2021 compared to $1.4 million tax expense for the same period in 2020. In connection with the intangibles impairment charge in the third quarter of 2021, the Company wrote-down the associated deferred tax liability by $8.6 million as a benefit.
- Net Income (Loss): Net income was $8.9 million, or $0.04 per basic and per diluted share, for the fourth quarter of 2021, compared to net loss of $15.0 million, or $0.11 per basic and diluted share, for the same period in 2020. For the year ended December 31, 2021, net loss was $0.3 million, or $0.00 per share, compared to net loss of $22.5 million, or $0.19 per share, for the same period in 2020. The full year decrease of $22.2 million in net loss was due primarily to the $20 million milestone achieved by Roche initiating a Phase II clinical study pursuant to the Roche License Agreement.
1As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course. |
About Vicineum™
Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of non-muscle invasive carcinoma in situ (CIS) of the bladder in patients previously treated with adequate or less than adequate BCG. Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached to the antibody binding fragment until it is internalized by the cancer cell. This fusion protein design is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in non-muscle invasive bladder cancer (NMIBC) cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently in the follow-up stage of a Phase 3 clinical trial in the US for the treatment of BCG-unresponsive NMIBC. In February 2021, the FDA accepted the Company’s Biologics License Application (BLA) file for Vicineum for the treatment of BCG-unresponsive NMIBC, granted Priority Review for the BLA and set a Prescription Drug User Fee Act (PDUFA) date of August 18, 2021. On August 13, 2021, the Company received a Complete Response Letter (CRL) from the FDA regarding its BLA for Vicineum. After meeting with the FDA, the Company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA. Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. For this reason, the activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as oportuzumab monatox, is currently in the follow-up stage of a Phase 3 clinical trial for the treatment of BCG-unresponsive NMIBC. In February 2021, the FDA accepted the Company’s BLA file for Vicineum for the treatment of BCG-unresponsive NMIBC, granted Priority Review for the BLA and set a PDUFA date of August 18, 2021. On August 13, 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum. After meeting with the FDA, the Company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China, the Middle East and North Africa (MENA) and Turkey, for which the Company has partnered with Qilu Pharmaceutical, Hikma Pharmaceuticals and Eczacibasi Pharmaceuticals Marketing (EIP), respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A, which is being developed for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. For more information, please visit the Company’s website at www.sesenbio.com.
COVID-19 Pandemic Potential Impact
Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on the Company. The Company has not yet experienced any disruptions to its operations as a result of COVID-19, however, the Company is not able to quantify or predict with certainty the overall scope of potential impacts to its business, including, but not limited to, its ability to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, its ability to raise capital and, if approved, its ability to commercialize Vicineum. Sesen Bio remains committed to the health and safety of patients, caregivers and employees.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “predict,” “target,” “potential,” “will,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. For example, statements regarding the anticipated regulatory path forward for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company’s belief that it has further clarity on the steps required to resubmit a BLA for Vicineum and to bring a therapy to market that it believes has the potential to save and improve the lives of patients, the Company’s belief that it has a clear understanding of what additional information regarding CMC is required for potential resubmission of a BLA, the Company’s ability to use Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum, the ability for future trials for Vicineum to proceed while the Company addresses CMC issues raised in the CRL, the Company’s plans to conduct an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company’s belief that the trial design for an additional Phase 3 clinical trial may include the following elements: a randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators’ choice of intravesical chemotherapy and inclusion of both patients who have received adequate BCG and patients who have received less-than-adequate BCG, the Company’s expectation that the anticipated randomized trial design is aligned with guidance the Company has received from the European Medicines Agency (EMA), which may help to coordinate the regulatory paths forward for Vicineum in the US and the European Union, the Company’s expectations to hold a Type C Meeting with the FDA to discuss study protocol for an additional Phase 3 clinical trial, any future payments to the Company pursuant to the Roche License Agreement including any future milestone payments and royalty payments, the Board’s continued support for the Company’s current management team, the Board’s belief that no changes or amendments relating to the Company’s prior disclosures to the SEC or FDA relating to Vicineum, the Phase 3 VISTA trial or the Company’s BLA for Vicineum are warranted, the Company’s intentions to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum, the impact of COVID-19 on the Company, including its ability to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, its ability to raise capital, and, if approved, its ability to commercialize Vicineum. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the risk that the Type C Meeting may not enable the Company to align with the FDA on the protocol for an additional Phase 3 clinical trial of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the occurrence of any event, change or other circumstances that could give rise to the termination of the Roche License Agreement, the risk that the Company may not resume its plans to pursue regulatory approval for Vicineum in the US or the European Union, the impact of the completion of the Review, including any related investigations, reviews or proceedings, shareholder lawsuits or reputational harm, the risk that the Company may not be able to reach agreement with the FDA on the protocol for an additional Phase 3 clinical trial for Vicineum, or other issues related to preparing for an additional Phase 3 clinical trial for Vicineum, including difficulties with clinical trial site selection and obtaining clinical trial materials and supplies, the risk that clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the additional clinical trial needed to address issues raised in the CRL, may fail to demonstrate safety and efficacy to the satisfaction of the FDA or the EMA, or otherwise produce favorable results, the risk that the FDA may not approve a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG if the Company resubmits a BLA at a future time, the risk that the European Commission may not approve the marketing authorization application (MAA) for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG if the Company resubmits a MAA at a future time, the risk that Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may cause undesirable side effects, serious adverse events or have other properties that could delay or halt clinical trials, delay or prevent its regulatory approval by the FDA or the European Commission, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
| SESEN BIO, INC. | ||||||
| CONSOLIDATED BALANCE SHEETS | ||||||
| (In thousands, except share and per share data) | ||||||
|
||||||
December 31, 2021 |
|
December 31, 2020 |
||||
| Assets |
|
|
|
|||
| Current assets: |
|
|
|
|||
| Cash and cash equivalents | $ |
162,636 |
|
$ |
52,389 |
|
| Accounts receivable |
|
21,011 |
|
|
- |
|
| Other receivables |
|
3,482 |
|
|
- |
|
| Prepaid expenses and other current assets |
|
18,476 |
|
|
7,478 |
|
| Restricted cash |
|
- |
|
|
3,000 |
|
| Total current assets |
|
205,605 |
|
|
62,867 |
|
|
|
|
||||
| Non-current assets: |
|
|
|
|||
| Restricted cash |
|
20 |
|
|
20 |
|
| Property and equipment, net |
|
43 |
|
|
123 |
|
| Intangible assets |
|
14,700 |
|
|
46,400 |
|
| Goodwill |
|
13,064 |
|
|
13,064 |
|
| Long term prepaid expenses |
|
7,192 |
|
|
- |
|
| Other assets |
|
123 |
|
|
349 |
|
| Total non-current assets | $ |
35,142 |
|
$ |
59,956 |
|
| Total Assets | $ |
240,747 |
|
$ |
122,823 |
|
|
|
|
||||
| Liabilities and Stockholders’ Equity (Deficit) |
|
|
|
|||
| Current liabilities: |
|
|
|
|||
| Accounts payable | $ |
2,853 |
|
$ |
3,102 |
|
| Accrued expenses |
|
8,255 |
|
|
3,973 |
|
| Deferred revenue |
|
- |
|
|
1,500 |
|
| Contingent consideration |
|
- |
|
|
8,985 |
|
| Other current liabilities |
|
460 |
|
|
489 |
|
| Total current liabilities |
|
11,568 |
|
|
18,049 |
|
|
|
|
||||
| Non-current liabilities: |
|
|
|
|||
| Contingent consideration, net of current portion |
|
52,000 |
|
|
99,855 |
|
| Deferred tax liability |
|
3,969 |
|
|
12,528 |
|
| Deferred revenue, net of current portion |
|
1,500 |
|
|
1,500 |
|
| Other non-current liabilities |
|
- |
|
|
118 |
|
| Total non-current liabilities |
|
57,469 |
|
|
114,001 |
|
| Total liabilities |
|
69,037 |
|
|
132,050 |
|
|
|
|
||||
| Stockholders’ Equity ( Deficit): |
|
|
|
|||
| Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020 |
|
- |
|
|
- |
|
| Common stock, $0.001 par value per share; 400,000,000 and 200,000,000 shares authorized at December 31, 2021 and 2020; 199,463,645 and 140,449,647 shares issued and outstanding at December 31, 2021 and 2020, respectively |
|
199 |
|
|
140 |
|
| Additional paid-in capital |
|
487,768 |
|
|
306,554 |
|
| Accumulated deficit |
|
(316,257) |
|
|
(315,921) |
|
| Total Stockholders’ Equity (Deficit) |
|
171,710 |
|
|
(9,227) |
|
| Total Liabilities and Stockholders’ Equity | $ |
240,747 |
|
$ |
122,823 |
|
| SESEN BIO, INC. | ||||||||||||
| CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) | ||||||||||||
| AND COMPREHENSIVE INCOME (LOSS) | ||||||||||||
| (In thousands, except per share data) | ||||||||||||
Three Months ended December 31, |
|
Twelve Months ended December 31, |
||||||||||
2021 |
2020 |
|
2021 |
2020 |
||||||||
| Revenue: |
|
|
|
|
|
|||||||
| License and related revenue | $ |
20,000 |
$ |
- |
|
$ |
26,544 |
$ |
11,236 |
|||
| Total revenue |
|
20,000 |
|
- |
|
|
26,544 |
|
11,236 |
|||
|
|
|
|
|
||||||||
| Operating expenses: |
|
|
|
|
|
|||||||
| Research and development |
|
7,039 |
|
5,566 |
|
|
25,312 |
|
29,191 |
|||
| General and administrative |
|
8,597 |
|
3,421 |
|
|
29,393 |
|
14,302 |
|||
| Restructuring charge |
|
6 |
|
- |
|
|
5,528 |
|
- |
|||
| Intangibles impairment charge |
|
|
- |
|
|
31,700 |
|
- |
||||
| Change in fair value of contingent consideration |
|
(4,600) |
|
5,640 |
|
|
(56,840) |
|
(11,180) |
|||
| Total operating expenses |
|
11,042 |
|
14,627 |
|
|
35,093 |
|
32,313 |
|||
|
|
|
|
|
||||||||
| Income (Loss) from Operations |
|
8,958 |
|
(14,627) |
|
|
(8,549) |
|
(21,077) |
|||
| Other income (expense), net |
|
(15) |
|
(69) |
|
|
(60) |
|
125 |
|||
| Income (Loss) Before Taxes |
|
8,944 |
|
(14,696) |
|
|
(8,609) |
|
(20,952) |
|||
| Benefit (provision) for income taxes |
|
- |
|
(313) |
|
|
8,273 |
|
(1,445) |
|||
| Net Income (Loss) and Comprehensive Income (Loss) After Taxes | $ |
8,944 |
$ |
(15,009) |
|
$ |
(336) |
$ |
(22,397) |
|||
|
|
|
|
|
||||||||
| Deemed dividend on adjustment of exercise price of certain warrants | $ |
- |
$ |
- |
|
$ |
- |
$ |
(147) |
|||
|
|
|
|
|
||||||||
| Net income (loss) attributable to common stockholders - basic | $ |
8,944 |
$ |
(15,009) |
|
$ |
(336) |
$ |
(22,544) |
|||
| Net income (loss) attributable to common stockholders - diluted | $ |
8,944 |
$ |
(15,009) |
|
$ |
(336) |
$ |
(22,544) |
|||
|
|
|
|
|
||||||||
| Net income (loss) per common share - basic | $ |
0.04 |
$ |
(0.11) |
|
$ |
(0.00) |
$ |
(0.19) |
|||
| Weighted-average common shares outstanding - basic |
|
199,464 |
|
131,522 |
|
|
182,323 |
|
118,221 |
|||
|
|
|
|
|
||||||||
| Net income (loss) per common share - diluted | $ |
0.04 |
$ |
(0.11) |
|
$ |
(0.00) |
$ |
(0.19) |
|||
| Weighted-average common shares outstanding - diluted |
|
199,464 |
|
131,522 |
|
|
182,323 |
|
118,221 |
|||
